Medical Aspects of Chemical Warfare (2008) - The Black Vault

Indexdescription and uses, 566M40A1 chemical-biological field maskscomponents, 565–566composition of, 565sizes, 565–566voicemitters, 565MacArthur, Gen. Douglascomments on US chemical warfare policy, 44–45Madden, J.F.1-chloroacetophenone research, 463Madderncyanide research, 373Mafenide acetatepediatric population and, 672treatment of mustard agent injuries, 280, 281, 671–672Malathionblood cholinesterase inhibition and, 165insecticide use, 158MANAA. See Medical aerosolized nerve agent antidoteManning, K.P.mustard agent exposure research, 313March, Chief of Staff Gen. Peyton C.Chemical Warfare Service and, 43Mark I kitsbuddy administration of, 190components, 651FDA approval for, 651nerve agent exposure treatment, 182–186, 188, 190, 192, 194,518, 520–521, 523, 651–652pediatric population and, 663, 683treatment of children and, 195Marrs, T.C.dibenz[b,f]-1,4-oxazepine research, 468hexachloroethane smoke research, 3272-chlorobenzylidene malononitrile research, 449Martin, L.J.“apoptosis-necrosis continuum,” 224Mass spectrometrybasis for, 692blood sample analysis for mustard agent exposure, 721, 725,726cholinesterase analysis, 701–702combined with liquid chromatography for mustard agent assays,713, 720–721lewisite exposure, 728mustard agent assays, 708, 716–717, 718, 720–721nerve agent assays and, 695, 699phosgene, 737sample preparation methods for the gas chromatographicmassspectrometric analysis of sulfur mustard adducts toblood biomolecules (exhibit), 724–725sample preparation time, 693Maxwell, D.M.fetal bovine serum AChE research, 245McBride, Capt. Lewis M.rifling of the Stokes mortar barrel, 118McCombie, Hamiltondiisopropyl fluorophosphate research, 48McLean, M.J.memantine research, 228McLeod, C.G., Jr.nerve-agent-induced brain damage research, 223McNamara, B.P.1-chloroacetophenone research, 4602-chlorobenzylidene malononitrile research, 446–447, 449, 450McNamara, Secretary of Defense Robert S.Project 112 and Project 80 and, 56MCU-2/P chemical-biological masksdescription and uses, 566MDMA. See 3,4-methylene-dioxymethylamphetamineMeade, Capt. JohnItalian-Ethiopian War observation report, 45–46MEDCOM. See US Army Medical CommandMedical aerosolized nerve agent antidotedescription, 651nerve agent exposure treatment, 186, 192, 651–652purpose of, 651–652shelf life issues, 652Medical chemical defense acquisition programsacquisition manufacturing strategy, 649acquisition process, 646business and contracting strategy, 650challenges, 650–651compound purity and, 651concept development (pre-milestone A activities), 647–648current good manufacturing processes and, 649intellectual property rights and, 649joint vaccine acquisition program, 647lifecycle management products, 651–652manufacturing challenges, 651medical chemical acquisition organizations, 646–647medical chemical acquisition processes and concerns, 647–651model for integrating pharmaceutical development, FDAregulatory, and the Department of Defense acquisition processes(figure), 648operations and support phase, 649production and deployment, 649products in advanced development, 652–654specific concerns, 650–651status of, 651–654sustainment programs, 652system development and demonstration, 649technology development and, 648–649test and evaluation strategy, 649–650transformational medical technologies initiative, 647US Food and Drug Administration and, 646, 647, 648–653Medical Defense Against Mustard Gas: Toxic Mechanisms and PharmacologicalImplications, 265Medical Identification and Treatment Systemsdescription, 4Medical identification and treatment systems joint product managementofficeacquisition business and contracting strategy and, 650advanced development of drugs and, 650“animal rule” for drug product approval and, 647, 651coordination with the technology base, 648lifecycle management, 649mission of, 647production and deployment plans and, 649responsibilities, 647streamlining of acquisition, 650technology development and, 648–649Medical Management of Chemical Agent Casualties Handbook, 184Medical management of chemical casualties. See also Medicalmanagement of chemical toxicity in pediatricsMedical Management of Chemical and Biological CasualtiesCourse, 763, 768post-World War I, 103–107pre-World War I, 78–79projections for the future, 108World War I, 79–102Medical management of chemical toxicity in pediatricsBroselow-Luten system: a systematic approach with colorcoding, 681–683xlvii